EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Optimal antiseptic skin preparation agents for minimizing surgical site infection following surgery: cost and cost-effectiveness analysis

Simon Deeming iD, Xenia Dolja-Gore, Jon Gani, Rosemary Carroll, Natalie Lott, John Attia iD, Penny Reeves, Stephen R Smith

BJS Open · 2024

DOI: 10.1093/bjsopen/zrad160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJS Open, 2024. Verfasst von Simon Deeming und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Impact, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. Hauptthemen laut MEDLINE: Povidone-Iodine, Anti-Infective Agents, Local. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: John Hunter Charitable Trust, Hunter Cancer Research Alliance, Hunter New England Health Research and Translation Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The application of antiseptic skin agents prior to incision minimizes the rate of surgical site infection. Despite their ubiquity, the optimal skin preparation agent remains uncertain. A retrospective economic analysis was conducted to complement the results from the NEWSkin Prep trial which prospectively compared three preparation agents.

Methods

A cost and cost-effectiveness analysis was performed from a healthcare service perspective to compare chlorhexidine with 70% ethanol, and aqueous povidone-iodine, against povidone-iodine with 70% ethanol. Resource use estimates accounted for hospital admissions, readmissions associated with surgical site infection, outpatient and general practitioner attendances, visits from community nurses and therapeutic consumables. The measure of effectiveness comprised the net difference in number of patients with surgical site infections per 1000 patients. Costs were compared using a two-sample Welch's t-test. Deterministic and probabilistic sensitivity analyses were performed to evaluate the incremental cost-effectiveness ratio.

Results

The null hypothesis that the mean costs for the trial arms were significantly different was not rejected (Welch's t-test P value: 0.771 for chlorhexidine with 70% ethanol against povidone-iodine with 70% ethanol; and 0.955 for aqueous povidone-iodine against povidone-iodine with 70% ethanol). Based on bootstrap averages, the chlorhexidine with 70% ethanol intervention generated 8.0 fewer surgical site infections per 1000 patients and net cost savings of €151,698 (Euros) per 1000 patients compared with povidone-iodine with 70% ethanol, and aqueous povidone-iodine produced a net cost saving of €37,494 per 1000 patients but generated an additional 11.6 surgical site infections per 1000 patients compared with povidone-iodine with 70% ethanol. The comparison of chlorhexidine with 70% ethanol to povidone-iodine with 70% ethanol was sensitive to the inclusion of cost outliers, while the comparison of aqueous povidone-iodine to povidone-iodine with 70% ethanol was sensitive to the estimated cost per surgical site infection.

Conclusion

Based on the outcomes from the NEWSkin Prep study, this economic analysis found no definitive evidence in favour of any one of the study comparators. Future model-based economic analyses of alternative skin preparations should critically address the quality of evidence and integrate the results from the NEWSkin Prep study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Povidone-IodineAnti-Infective Agents, LocalHumansSurgical Wound InfectionChlorhexidineCost-Effectiveness AnalysisRetrospective StudiesEthanol2-Propanol

Substanzen

Povidone-IodineChlorhexidineAnti-Infective Agents, LocalEthanol2-Propanol

Autor:innen und Institutionen

  • Health Economics and Impact, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
  • School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia.
  • Hunter Surgical Clinical Research Unit, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
  • Center for Clinical Epidemiology and Biostatistics, The University of Newcastle, Callaghan, New South Wales, Australia.

ORCID-Profile: Simon Deeming, John Attia

Förderung

  • John Hunter Charitable Trust
  • Hunter Cancer Research Alliance
  • Hunter New England Health Research and Translation Centre
  • Cancer Institute NSW

Zitieren

APA

Deeming, S., Dolja-Gore, X., Gani, J., Carroll, R., Lott, N., Attia, J., Reeves, P., & Smith, S. R. (2024). Optimal antiseptic skin preparation agents for minimizing surgical site infection following surgery: cost and cost-effectiveness analysis. BJS Open. https://doi.org/10.1093/bjsopen/zrad160

Vancouver

Deeming S, Dolja-Gore X, Gani J, Carroll R, Lott N, Attia J, et al. Optimal antiseptic skin preparation agents for minimizing surgical site infection following surgery: cost and cost-effectiveness analysis. BJS Open. 2024. doi:10.1093/bjsopen/zrad160

BibTeX
@article{Deeming2024,
  author = {Deeming, Simon and Dolja-Gore, Xenia and Gani, Jon and Carroll, Rosemary and Lott, Natalie and Attia, John and Reeves, Penny and Smith, Stephen R},
  title = {Optimal antiseptic skin preparation agents for minimizing surgical site infection following surgery: cost and cost-effectiveness analysis},
  journal = {BJS Open},
  year = {2024},
  doi = {10.1093/bjsopen/zrad160}
}
Kostenlos starten →